BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PSI-7977: Phase IIb data

Data from 121 treatment-naïve patients with HCV genotype 1 infection in the U.S. Phase IIb PROTON trial showed that 98% of patients receiving 200 (n=48) or 400 mg (n=47) PSI-7977 plus standard of care (SOC; Pegasys peginterferon alfa-2a and Copegus ribavirin) achieved an RVR, defined as undetectable HCV RNA levels (<15 IU/mL) at week 4, vs. 19% for placebo plus SOC (n=26). Additionally,...

Read the full 315 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >